Imatinib Viatris

Imatinib, the active ingredient in Imatinib Viatris, is a tyrosine kinase inhibitor presented as an oral formulation for oral use. It is indicated for chronic myeloid leukemia, Philadelphia chromosome‑positive acute lymphoblastic leukemia and gastrointestinal stromal tumor in adult patients. GNH USA supplies Imatinib Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Imatinib targets abnormal tyrosine‑kinase signaling that drives several hematologic and solid‑tumor cancers.

- Chronic myeloid leukemia (CML): reduces leukemic cell proliferation and helps achieve durable disease control. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): blocks BCR‑ABL activity to improve remission rates. - Gastrointestinal stromal tumor (GIST): inhibits c‑KIT and PDGFR signaling, limiting tumor growth.

Imatinib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea - Peripheral edema - Muscle cramps or pain - Fatigue - Diarrhea - Skin rash

Serious or Rare Side Effects: - Severe neutropenia or thrombocytopenia - Hepatotoxicity (elevated transaminases, hepatitis) - Cardiac failure or reduced left‑ventricular function - Pulmonary arterial hypertension - Severe cutaneous reactions (Stevens‑Johnson syndrome, toxic epidermal necrolysis) - Major hemorrhage or bleeding disorders

Before initiating therapy, clinicians should assess baseline organ function and monitor patients regularly. - Monitor blood counts: perform routine CBC to detect cytopenias. - Assess liver function: periodic LFTs to identify hepatotoxicity. - Check cardiac status: evaluate for signs of heart failure or pulmonary hypertension. - Avoid strong CYP3A4 inhibitors: co‑administration may increase imatinib exposure. - Store below 25°C: keep in the original pack, protect from moisture.

Imatinib interacts with several drug classes that can alter its plasma concentration or increase toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may markedly raise imatinib levels. - Antacids containing aluminum or magnesium: can reduce oral absorption. - Warfarin: concurrent use may enhance anticoagulant effect and increase bleeding risk.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower efficacy. - QT‑prolonging agents (e.g., sotalol, quinidine): increase risk of arrhythmia. - Live attenuated vaccines: potential reduced immunogenicity.